Who is this relevant for?
- Manufacturers evaluating market entry
- Distributors monitoring sourcing opportunities
Chiesi Group, the Italian family-owned drugmaker, is paying $1.9 billion in cash to acquire KalVista Pharmaceuticals. The deal gives Chiesi full ownership of EKTERLY (sebetralstat), an oral on-demand treatment for hereditary angioedema (HAE), a rare disease marked by sudden and dangerous swelling attacks.
The transaction values KalVista at $27 per share, a 40% premium over its prior closing price. KalVista stock jumped nearly 39% on the announcement. Chiesi plans to fund the acquisition with cash on hand and debt, having finished 2025 with €729 million in net cash. The deal is expected to close in the third quarter of 2026, pending regulatory approvals.
This is Chiesi’s largest-ever acquisition. The company is betting that EKTERLY will deepen its US commercial footprint and help it reach a €6 billion revenue target by 2030. For a rare disease drug, EKTERLY addresses a small patient population, but high pricing and limited competition make such assets attractive to large drugmakers seeking steady growth beyond older product lines.
The all-cash structure gives KalVista shareholders a clear payout, and the stock quickly traded near the offer price, reflecting limited closing risk. The deal underscores how late-stage or newly approved rare disease drugs can command premiums even when the broader biotech sector is under pressure.
For manufacturers and distributors tracking rare disease opportunities, Chiesi’s move signals continued confidence in oral HAE therapies. The acquisition also points to the multi-year horizon typical in pharma dealmaking — approvals, US launch, and demand build-out will take time.